Clinical trials
Metastatic Melanoma clinical trials
Below are recruiting metastatic melanoma clinical trials, each written for real people, not researchers. We’re tracking 123 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06743126RecruitingPhase 3
IMA203 vs standard treatment for advanced skin cancer
This trial tests a new cell therapy called IMA203 against standard treatments for people with advanced melanoma (a type of skin cancer) that has spread or can't be removed. It may be an option if you have already tried certain treatments and your cancer has a specific cell marker (HLA-A*02:01).
Phoenix, ArizonaAges 18 years+ - NCT07223411Recruiting
Opdualag vs. cemiplimab/fianlimab for melanoma
This trial compares two treatments for advanced melanoma that cannot be removed with surgery or has spread. It studies how these treatments affect the immune response in tumors and blood, and requires extra biopsies and blood draws.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05498792RecruitingEarly Phase 1
Trial testing CBL0137 with two immunotherapy drugs for melanoma
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05877430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug plus pembrolizumab for advanced cancers
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
Irvine, CaliforniaAges 18 years+ - NCT07130032RecruitingPhase 2
Immunotherapy combo for advanced lung cancer or melanoma
This trial tests a combination of immunotherapy drugs (anti-PD-1/PD-L1 antibodies) plus bevacizumab and a low-dose chemotherapy called cyclophosphamide for people with advanced lung cancer or melanoma who have already been on immunotherapy and their cancer has progressed.
Saint Petersburg, Sankt-PeterburgAges 18 years+ - NCT03947385RecruitingPhase 1/Phase 2
First drug test for metastatic uveal melanoma with specific gene changes
This Phase 1/2 trial studies IDE196 in adults with metastatic uveal melanoma that has certain gene mutations or fusions. It’s mainly testing safety and correct dosing, and may help shrink tumors in patients matched to the tumor’s genetic changes.
Los Angeles, CaliforniaAges 18 years+ - NCT06070012RecruitingPhase 2
Tebentafusp for untreated metastatic uveal melanoma
This trial tests a new drug called tebentafusp for people with uveal melanoma that has spread to other parts of the body and who have not yet received any treatment for the metastatic disease. It requires a specific genetic marker (HLA-A*0201) and focuses on whether the drug can shrink or slow the growth of tumors.
Aurora, ColoradoAges 18 years+ - NCT06626516RecruitingPhase 1/Phase 2
Tebentafusp and LDT for metastatic uveal melanoma
This trial tests a combination of two drugs (tebentafusp and a liver-directed treatment called LDT) for people with uveal melanoma that has spread to the liver. The goal is to see if this combination helps shrink tumors and improve outcomes.
Philadelphia, PennsylvaniaAges 18 years+ - NCT01438658Recruiting
Test blood markers to help diagnose metastatic uveal melanoma
This study checks whether blood “biomarkers” (measurable signs in serum) can help diagnose metastatic uveal melanoma. If you have uveal melanoma, the study may look at how useful these blood tests are for spotting spread to other parts of the body.
JerusalemAges Any age - NCT07280832RecruitingPhase 1/Phase 2
Study of JMT108 for advanced melanoma
This trial tests a new drug, JMT108, for people with advanced melanoma that can't be removed by surgery or has spread. It's for those who have tried other treatments or have no good options left.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07364474Recruiting
Immune response to liver perfusion therapy for eye melanoma
This study tests how well the liver responds to a treatment called percutaneous hepatic perfusion with melphalan (chemotherapy delivered directly to the liver) in people with uveal melanoma that has spread to the liver. The goal is to see how the immune system reacts and if the treatment helps control the disease.
Boston, MassachusettsAges 18 years+ - NCT07057596RecruitingPhase 2
Tebentafusp before surgery for uveal melanoma in the liver
This trial tests a drug called tebentafusp before surgery for uveal melanoma that has spread to the liver. The goal is to see if giving the drug first can shrink the tumors and make surgery more effective.
Berlin, State of BerlinAges 18 years+ - NCT05909618RecruitingPhase 2
Crizanlizumab with nivolumab for brain-spread melanoma or glioblastoma
This Phase 2 study tests crizanlizumab alone or with nivolumab to treat people with certain brain tumors that have spread to the brain (melanoma) or glioblastoma. The goal is to see whether this approach can control the disease and improve outcomes.
Ramat Gan, IsraelAges 18 years+ - NCT05649683Recruiting
Blood immune testing to predict melanoma response to immunotherapy
This study checks how your immune system behaves (through an immune testing process) to see if it can predict how well advanced melanoma will respond to checkpoint inhibitor treatment. It may help doctors choose the right treatment sooner, without guessing.
Nice, Alpes-maritimesAges 18 years+ - NCT06246916RecruitingPhase 3
Testing a new immunotherapy combo for advanced melanoma
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
Chandler, ArizonaAges 18 years+ - NCT07203391RecruitingPhase 1
Tebentafusp and roginolisib for uveal melanoma
This trial tests a combination of two drugs, tebentafusp and roginolisib, for people with uveal melanoma that has spread or can't be removed. It aims to improve how long the immune system stays active against the cancer.
Sydney, New South WalesAges 18 years+ - NCT06545682RecruitingPhase 1
Study of alpelisib and pembrolizumab for advanced breast cancer or melanoma
This trial tests a combination of two drugs, alpelisib and pembrolizumab, for people with advanced triple-negative breast cancer or melanoma that has spread. The goal is to see if the combination can help shrink tumors, including those that have spread to the brain.
Houston, TexasAges 18 years+ - NCT07302607Recruiting
Melanoma immunotherapy study at Strasbourg Hospital
This study looks back at medical records to find out what factors helped people with advanced melanoma respond completely to immunotherapy. It includes patients treated at a specific hospital in France between 2013 and 2021.
StrasbourgAges 18 years+ - NCT05970497RecruitingPhase 1/Phase 2
KB707 trial for advanced solid tumors after other treatments
This early-stage trial tests KB707 in people with locally advanced or metastatic solid tumors that have not responded well to standard treatments. If you qualify, you may receive KB707 to see how well it can shrink tumors or control the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT05856565Recruiting
AI study using skin scar images to predict anti-PD-1 response
This study tests an artificial intelligence (AI) tool that looks at images of skin “peri-scar” areas to predict how well anti-PD-1 immunotherapy will work. It may help doctors better choose treatment for people with hard-to-operate (inoperable) melanoma or certain skin cancers.
Besançon, Bourgogne-Franche-ComtéAges 18 years+ - NCT02621021RecruitingPhase 2
Metastatic melanoma trial using immune cells plus IL-2
This Phase 2 study tests a form of immune cell therapy for metastatic melanoma, using tumor-infiltrating lymphocytes (TIL) and IL-2. Some people also may receive pembrolizumab, and the goal is to see if this approach can shrink the cancer.
Bethesda, MarylandAges 18–72 - NCT07237594RecruitingPhase 1
IL-17 blocker to prevent immunotherapy side effects
This trial tests whether a drug called secukinumab (an IL-17 blocker) can prevent or reduce severe side effects when you restart immunotherapy for advanced melanoma. It's for people who've had immune-related side effects before and need to continue treatment.
Durham, North CarolinaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05267626RecruitingPhase 1/Phase 2
AU-007 antibody for hard-to-remove or spread skin and lung cancers
This trial tests AU-007, an antibody that targets the IL-2 pathway, in people with certain advanced skin (melanoma) or lung (NSCLC) cancers. It’s designed for cancers that have already progressed after prior immune and other treatments, to see if AU-007 can shrink tumors or control disease.
Miami, FloridaAges 18 years+
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic melanoma?
- Yes. Clin2 currently lists 123 recruiting metastatic melanoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic melanoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic melanoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.